REG - Synairgen plc - Board Change

SynairgenAnnouncement

05/09/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240905:nRSE9560Ca&default-theme=true

RNS Number : 9560C  Synairgen plc  05 September 2024

 

Synairgen plc

('Synairgen' or the 'Company')

Board Change

 

Southampton, UK - 5 September 2024: Synairgen plc (LSE: SNG), the respiratory
company developing SNG001, an investigational formulation for inhalation
containing the broad-spectrum antiviral protein interferon beta, today
announces that, following 18 years of service, Dr. Phillip Monk is stepping
down from the Board and will leave the Company on 31 December 2024.

With Synairgen's resources dedicated to the clinical development of SNG001,
Dr. Marcin Mankowski became the Company's Chief Medical Officer in 2023 and
will continue to lead the clinical development strategy for SNG001.

The Company looks forward to announcing further Board changes ahead of hosting
its Annual General Meeting in early October.

Simon Shaw, Chairman of the Board of Synairgen, said: "On behalf of the Board
and the team at Synairgen, I would like to express my thanks to Phill for his
significant contribution over many years, particularly for progressing the
early-stage clinical development of SNG001. We wish him the very best for the
future."

For further enquiries, please contact:

Synairgen plc

Media@synairgen.com (mailto:Media@synairgen.com)

Tel: + 44 (0) 23 8051 2800

 

Cavendish Capital Markets Limited (NOMAD and Joint Broker)

Geoff Nash, Camilla Hume, Trisyia Jamaludin (Corporate Finance)

Sunila de Silva (ECM)

Tel: + 44 (0) 20 7220 0500

 

Deutsche Numis (Joint Broker)

Freddie Barnfield, Duncan Monteith, Euan Brown

Tel: + 44 (0) 20 7260 1000

 

ICR Consilium (Financial Media and Investor Relations)

Mary-Jane Elliott, Namrata Taak, Lucy Featherstone

synairgen@consilium-comms.com (mailto:synairgen@consilium-comms.com)

Tel: +44 (0) 20 3709 5700

 

Notes for Editors

About Synairgen

Synairgen is a UK-based respiratory company focused on drug discovery and the
development of SNG001 (inhaled interferon beta) as potentially the first
host-targeted, broad-spectrum antiviral treatment delivered directly into the
lungs for severe viral lung infections.

Millions of people globally are hospitalised every year due to viral lung
infections and there are currently no approved antiviral therapies for the
majority of these patients. Synairgen is developing SNG001 to address this
need.

Synairgen is quoted on AIM (LSE: SNG). For more information about Synairgen,
please see www.synairgen.com (http://www.synairgen.com)

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOAQZLFBZKLXBBK